BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 16414180)

  • 21. A 3D QSAR model of 17beta-HSD1 inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core applying molecular dynamics simulations and ligand-protein docking.
    Karkola S; Lilienkampf A; Wähälä K
    ChemMedChem; 2008 Mar; 3(3):461-72. PubMed ID: 18224704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
    Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
    J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective insensitivity of ZR-75-1 human breast cancer cells to 2-methoxyestradiol: evidence for type II 17beta-hydroxysteroid dehydrogenase as the underlying cause.
    Liu ZJ; Lee WJ; Zhu BT
    Cancer Res; 2005 Jul; 65(13):5802-11. PubMed ID: 15994956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases.
    Oster A; Hinsberger S; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    J Med Chem; 2010 Nov; 53(22):8176-86. PubMed ID: 20977238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrone and estradiol C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase.
    Poirier D; Chang HJ; Azzi A; Boivin RP; Lin SX
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):236-8. PubMed ID: 16337735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.
    Day JM; Foster PA; Tutill HJ; Parsons MF; Newman SP; Chander SK; Allan GM; Lawrence HR; Vicker N; Potter BV; Reed MJ; Purohit A
    Int J Cancer; 2008 May; 122(9):1931-40. PubMed ID: 18183589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estrone.
    Ayan D; Maltais R; Roy J; Poirier D
    Mol Cancer Ther; 2012 Oct; 11(10):2096-104. PubMed ID: 22914440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemical synthesis, characterisation and biological evaluation of furanic-estradiol derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 1.
    Farhane S; Laplante Y; Poirier D
    Med Chem; 2011 Mar; 7(2):80-91. PubMed ID: 21222612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of a new class of bicyclic substituted hydroxyphenylmethanones as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors for the treatment of osteoporosis.
    Wetzel M; Gargano EM; Hinsberger S; Marchais-Oberwinkler S; Hartmann RW
    Eur J Med Chem; 2012 Jan; 47(1):1-17. PubMed ID: 21945251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).
    Bey E; Marchais-Oberwinkler S; Werth R; Negri M; Al-Soud YA; Kruchten P; Oster A; Frotscher M; Birk B; Hartmann RW
    J Med Chem; 2008 Nov; 51(21):6725-39. PubMed ID: 18855374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemical synthesis, characterisation and biological evaluation of lactonic-estradiol derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 1.
    Farhane S; Fournier MA; Poirier D
    J Steroid Biochem Mol Biol; 2013 Sep; 137():322-31. PubMed ID: 23685015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Messinger J; Hirvelä L; Husen B; Kangas L; Koskimies P; Pentikäinen O; Saarenketo P; Thole H
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):192-8. PubMed ID: 16413669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C6-(N,N-butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation.
    Cadot C; Laplante Y; Kamal F; Luu-The V; Poirier D
    Bioorg Med Chem; 2007 Jan; 15(2):714-26. PubMed ID: 17110114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemical Synthesis and Biological Evaluation of 3-Substituted Estrone/Estradiol Derivatives as 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors Acting via a Reverse Orientation of the Natural Substrate Estrone.
    Ngueta AD; Roy J; Maltais R; Poirier D
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
    Lawrence HR; Vicker N; Allan GM; Smith A; Mahon MF; Tutill HJ; Purohit A; Reed MJ; Potter BV
    J Med Chem; 2005 Apr; 48(8):2759-62. PubMed ID: 15828812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triazole ring-opening leads to the discovery of potent nonsteroidal 17β-hydroxysteroid dehydrogenase type 2 inhibitors.
    Xu K; Al-Soud YA; Wetzel M; Hartmann RW; Marchais-Oberwinkler S
    Eur J Med Chem; 2011 Dec; 46(12):5978-90. PubMed ID: 22037253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells.
    Brooks JD; Thompson LU
    J Steroid Biochem Mol Biol; 2005 Apr; 94(5):461-7. PubMed ID: 15876411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Org OD14 (Livial) and its metabolites on 17 beta-hydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and T-47D breast cancer cells.
    Chetrite GS; Kloosterboer HJ; Philippe JC; Pasqualini JR
    Anticancer Res; 1999; 19(1A):261-7. PubMed ID: 10226552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
    Oster A; Klein T; Werth R; Kruchten P; Bey E; Negri M; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    Bioorg Med Chem; 2010 May; 18(10):3494-505. PubMed ID: 20413314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
    Pasqualini JR; Chetrite GS
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.